XOMA (NASDAQ:XOMA) was upgraded by research analysts at TheStreet from an “e+” rating to a “c-” rating in a research note issued to investors on Wednesday.
Several other analysts also recently commented on XOMA. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of XOMA in a research note on Thursday, August 10th. Wedbush reaffirmed a “hold” rating on shares of XOMA in a research note on Monday, August 14th. Finally, Zacks Investment Research downgraded XOMA from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $30.00.
XOMA (NASDAQ XOMA) traded up $0.94 during mid-day trading on Wednesday, hitting $31.14. The stock had a trading volume of 229,612 shares, compared to its average volume of 151,270. The company has a debt-to-equity ratio of 3.53, a quick ratio of 3.45 and a current ratio of 3.45. XOMA has a one year low of $3.96 and a one year high of $33.00.
Institutional investors have recently modified their holdings of the stock. California Public Employees Retirement System increased its holdings in XOMA by 95.5% during the 1st quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 10,640 shares in the last quarter. OxFORD Asset Management LLP bought a new position in XOMA during the 3rd quarter worth about $543,000. Finally, EAM Investors LLC bought a new position in XOMA during the 3rd quarter worth about $835,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “XOMA (XOMA) Upgraded to C- by TheStreet” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/xoma-xoma-upgraded-to-c-by-thestreet.html.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.